Glenmark is continuing to build up steam for the firm’s Ryaltris (olopatadine hydrochloride/mometasone furoate) 665mcg/25mcg nasal spray after receiving an approval for the product from the Ministry of Health of the Russian Federation.
With the approval in hand, the Indian firm believes launch in Russia is possible in the three-month period ending 30...



